Bayer Group Key Data

 

 

Q2 2017

 

Q2 2018

 

Change

 

H1 2017

 

H1 2018

 

Change

 

Full Year 2017

 

 

€ million

 

€ million

 

%

 

€ million

 

€ million

 

%

 

€ million

2017 figures restated

1

For definition see Annual Report 2017, Chapter “Alternative Performance Measures Used by the Bayer Group.”

2

Employees calculated as full-time equivalents (FTEs)

Sales

 

8,714

 

9,481

 

+8.8

 

18,394

 

18,619

 

+1.2

 

35,015

Change (adjusted for currency and portfolio effects)1

 

 

 

 

 

+8.5

 

 

 

 

 

+5.1

 

+1.5%

Change in sales1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Volume

 

−2.7%

 

+9.9%

 

 

 

+1.0%

 

+6.4%

 

 

 

+2.3%

Price

 

−0.1%

 

−1.4%

 

 

 

+0.1%

 

−1.3%

 

 

 

−0.8%

Currency

 

+1.1%

 

−5.8%

 

 

 

+1.8%

 

−6.7%

 

 

 

−1.4%

Portfolio

 

+0.1%

 

+6.1%

 

 

 

+0.1%

 

+2.8%

 

 

 

+0.1%

EBITDA1

 

2,135

 

2,017

 

−5.5

 

5,134

 

4,835

 

−5.8

 

8,563

Special items1

 

(112)

 

(318)

 

 

 

(167)

 

(396)

 

 

 

(725)

EBITDA before special items1

 

2,247

 

2,335

 

+3.9

 

5,301

 

5,231

 

−1.3

 

9,288

EBITDA margin before special items1

 

25.8%

 

24.6%

 

 

 

28.8%

 

28.1%

 

 

 

26.5%

EBIT1

 

1,463

 

1,351

 

−7.7

 

3,890

 

3,661

 

−5.9

 

5,903

Special items1

 

(244)

 

(363)

 

 

 

(346)

 

(441)

 

 

 

(1,227)

EBIT before special items1

 

1,707

 

1,714

 

+0.4

 

4,236

 

4,102

 

−3.2

 

7,130

Financial result

 

(369)

 

(322)

 

−12.7

 

(665)

 

(192)

 

+71.1

 

(1,326)

Net income (from continuing and discontinued operations)

 

1,224

 

799

 

−34.7

 

3,307

 

2,753

 

−16.8

 

7,336

Earnings per share1 from continuing and discontinued operations (€)

 

1.38

 

0.87

 

−37.0

 

3.74

 

3.06

 

−18.2

 

8.29

Core earnings per share1 from continuing operations (€)

 

1.52

 

1.54

 

+1.3

 

3.80

 

3.77

 

−0.8

 

6.64

Net cash provided by operating activities (from continuing and discontinued operations)

 

2,313

 

2,240

 

−3.2

 

3,154

 

2,898

 

−8.1

 

8,134

Cash outflows for capital expenditures

 

476

 

459

 

−3.6

 

891

 

808

 

−9.3

 

2,418

Research and development expenses

 

1,097

 

1,261

 

+14.9

 

2,191

 

2,301

 

+5.0

 

4,504

Depreciation, amortization and impairments

 

672

 

666

 

−0.9

 

1,244

 

1,174

 

−5.6

 

2,660

Number of employees at end of period2

 

99,720

 

124,055

 

+24.4

 

99,720

 

124,055

 

+24.4

 

99,820

Personnel expenses (including pension expenses)

 

2,345

 

2,566

 

+9.4

 

4,981

 

5,004

 

+0.5

 

9,528

Compare to Last Year